Secukinumab Dosage

Medically reviewed by Drugs.com. Last updated on Feb 13, 2025.

Applies to the following strengths: 150 mg/mL; 75 mg/0.5 mL; 300 mg/2 mL; 25 mg/mL

Usual Adult Dose for Plaque Psoriasis

300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

For some patients: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter may be acceptable

Comments:

Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.

Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Usual Adult Dose for Psoriatic Arthritis

IV DOSAGE:

With a Loading Dose:
Loading dose: 6 mg/kg IV at Week 0
Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)

SUBCUTANEOUS DOSAGE:
For Psoriatic Arthritis Patients With Coexistent Moderate to Severe Plaque Psoriasis: 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

For some patients: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter may be acceptable

For Other Psoriatic Arthritis Patients:

With a loading dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Without a loading dose: 150 mg subcutaneously every 4 weeks
If active psoriatic arthritis continues: Consider increasing the dosage to 300 mg subcutaneously every 4 weeks.

Comments:

This drug may be administered with or without methotrexate.
IV dosage: This drug should be administered over 30 minutes.
Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.

Use: For the treatment of active psoriatic arthritis

Usual Adult Dose for Ankylosing Spondylitis

IV DOSAGE:

With a Loading Dose:
Loading dose: 6 mg/kg IV at Week 0
Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)

SUBCUTANEOUS DOSAGE:

With a Loading Dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Without a Loading Dose: 150 mg subcutaneously every 4 weeks
If Active Ankylosing Spondylitis Continues: Consider increasing the dosage to 300 mg subcutaneously every 4 weeks.

Comments:

IV dosage: This drug should be administered over 30 minutes.
Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.

Use: For the treatment of patients with active ankylosing spondylitis

Usual Adult Dose for Non-Radiographic Axial Spondyloarthritis

IV DOSAGE:

With a Loading Dose:
Loading dose: 6 mg/kg IV at Week 0
Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)

SUBCUTANEOUS DOSAGE:

With a Loading Dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Without a Loading Dose: 150 mg subcutaneously every 4 weeks

Comments:

IV dosage: This drug should be administered over 30 minutes.
Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.

Use: For the treatment of patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation

Usual Adult Dose for Hidradenitis Suppurativa

300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

If patient response is not adequate: Consider increasing the dosage to 300 mg subcutaneously every 2 weeks.

Comments:

Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.

Use: For the treatment of patients with moderate to severe hidradenitis suppurativa

Usual Pediatric Dose for Plaque Psoriasis

6 years and older:

Weight less than 50 kg (at time of dosing): 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Weight at least 50 kg (at time of dosing): 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Usual Pediatric Dose for Juvenile Psoriatic Arthritis

2 years and older:

Weight 15 to less than 50 kg: 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Weight at least 50 kg: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

Comments:

This drug may be administered with or without methotrexate.

Use: For the treatment of active juvenile psoriatic arthritis

Usual Pediatric Dose for Enthesitis-Related Arthritis

4 years and older:

Weight 15 to less than 50 kg: 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Weight at least 50 kg: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

Use: For the treatment of active enthesitis-related arthritis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

Previous serious hypersensitivity reaction to the active component or any of the ingredients

IV administration: Safety and efficacy have not been established in patients younger than 18 years.

Subcutaneous administration:

Pediatric plaque psoriasis: Safety and efficacy have not been established in patients younger than 6 years.
Juvenile psoriatic arthritis: Safety and efficacy have not been established in pediatric patients weighing less than 15 kg or younger than 2 years.
Enthesitis-related arthritis: Safety and efficacy have not been established in pediatric patients weighing less than 15 kg or younger than 4 years.
Hidradenitis suppurativa: Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Before starting this drug, evaluate for active/latent tuberculosis (TB).
Do not start this drug in patients with active TB infection; initiate treatment of latent TB before starting this drug.
Before starting this drug, complete all age-appropriate vaccinations as recommended by current immunization guidelines.

IV Infusion:

Solution in vials is for IV use in adult patients only.
IV infusion is only for use by a health care professional in a health care setting.
Administer IV infusion only in adults with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.
Use only an infusion set with an in-line, sterile, nonpyrogenic, low protein-binding filter (pore size 0.2 micrometer).
Administer the infusion at a flow rate of about 3.3 mL/min for a 100 mL bag or 1.7 mL/min for a 50 mL bag (total administration time: 30 minutes).
When infusion is complete, flush the line with at least 50 mL of 0.9% Sodium Chloride Injection, USP to ensure all of the drug in the line has been administered.
Do not infuse this drug concomitantly in the same IV line with other drugs.

Subcutaneous Injection:

UnoReady pens, Sensoready pens, and prefilled syringes are for subcutaneous use only.
After proper training in subcutaneous injection technique:
Adult patients may self-administer this drug or be injected by a caregiver.
For pediatric patients, an adult caregiver should prepare and inject this drug; self-administration is not recommended.
Administer each subcutaneous injection at a different anatomic location (e.g., upper arms, thighs, any quadrant of abdomen) than the previous injection; do not administer into areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
A caregiver or health care provider may administer this drug subcutaneously in the upper, outer arm.
Consult the Instructions for Use for more detailed instructions on the administration of this drug for patients and caregivers.

Storage requirements:

Store refrigerated at 2C to 8C (36F to 46F); do not freeze. Keep in original carton to protect from light until time of use. Do not shake.
IV infusion: Administer the diluted solution as soon as possible; if not administered immediately, store the diluted solution either:
At room temperature (20C to 25C [68F to 77F]) for no more than 4.5 hours, from the start of preparation (piercing the first vial) to the completion of infusion.
Under refrigeration (2C to 8C [36F to 46F]) for no more than 24 hours, from the start of preparation (piercing the first vial) to the completion of infusion; this time includes refrigeration of the diluted solution and the time to allow it to warm to room temperature. Protect the diluted solution from light while stored under refrigeration.
Subcutaneous injection: If the Sensoready Pens and prefilled syringes are removed from refrigeration, they may be stored for up to 4 days at room temperature (not to exceed 30C [86F]).
Write the date the product is removed from and returned to the refrigerator.
Discard the product if stored outside the refrigerator more than 4 days.
The product may be returned to the refrigerator only 1 time and must be stored at 2C to 8C (36F to 46F) until used or expired.
Discard any unused product.

Reconstitution/preparation techniques:

The manufacturer product information should be consulted.
IV infusion: This drug must be diluted before administration; do not shake.
Before dilution, allow the solution to sit for about 20 minutes at room temperature (20C to 25C [68F to 77F]).
Use a 100 mL infusion bag for the loading dose in adult patients at any weight and for the maintenance dose in adult patients weighing more than 52 kg.
Use a 50 mL infusion bag for the maintenance dose in adult patients weighing 52 kg or less; if a 50 mL infusion bag is not available, use a 100 mL infusion bag and withdraw and discard 50 mL of saline.
Subcutaneous injection: The Instructions for Use should be consulted for more detailed instructions on the preparation of this drug for patients and caregivers.
Before administration, remove this drug from the refrigerator and allow it to reach room temperature (Sensoready pen [150 mg/mL] and prefilled syringes [150 mg/mL, 75 mg/0.5 mL]: 15 to 30 minutes; UnoReady pen and prefilled syringe [300 mg/2 mL]: 30 to 45 minutes) without removing the needle cap.

IV compatibility:

Compatible: 0.9% Sodium Chloride Injection, USP
No physical or biochemical compatibility studies have been conducted to evaluate IV coadministration with other drugs.

General:

This drug should be used under the guidance and supervision of a health care provider.
Cases of anaphylaxis and angioedema have been reported during therapy.
The removable caps of the Sensoready pen (150 mg/mL) and prefilled syringes (150 mg/mL, 75 mg/0.5 mL) contain natural rubber latex; these caps should not be handled by latex-sensitive individuals as they may cause an allergic reaction.

Monitoring:

Gastrointestinal: For signs/symptoms of inflammatory bowel disease (during therapy)
Infections/Infestations: For active or latent TB (before starting therapy); for signs/symptoms of active TB (during and after therapy)

Patient advice:

Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use).
It is important to contact your physician if any symptoms of infection develop.
Seek immediate medical attention if any symptoms of serious hypersensitivity reactions develop.
Seek medical advice if signs/symptoms of eczema develop.
Before potential vaccination, inform the health care practitioner that you are taking this drug.